Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified infiltration articaine versus inferior alveolar nerve block lidocaine for mandibular molars with irreversible pulpitis
IRCT20200301046656N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of articaine, lidocaine and epinephrine in irreversible pulpitis (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Response to electric pulp test, Pain during injection and 2 more. Started Jan 2021; status: completed.
02
Drugs
articainelidocaineepinephrine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on IRCT20200301046656N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200301046656N1.